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A low-resolution structure of the catalytic subunit CK2 of
human protein kinase CK2 (formerly known as casein kinase
2) in complex with the ATP-competitive inhibitor resorufin is
presented. The structure supplements previous human CK2
structures in which the interdomain hinge/helix D region
adopts a closed conformation correlating to a canonically
established catalytic spine as is typical for eukaryotic protein
kinases. In the corresponding crystal packing the hinge/helix
D region is nearly unaffected by crystal contacts, so that
largely unbiased conformational adaptions are possible. This
is documented by published human CK2 structures with the
same crystal packing but with an open hinge/helix D region,
one of which has been redetermined here with a higher
symmetry. An overview of all published human CK2 crystal
packings serves as the basis for a discussion of the factors that
determine whether the open or the closed hinge/helix D
conformation is adopted. Lyotropic salts in crystallization
support the closed conformation, in which the Phe121 side
chain complements the hydrophobic catalytic spine ensemble.
Consequently, genuine ligand effects on the hinge/helix D
conformation can be best studied under moderate salt
conditions. Ligands that stabilize either the open or the closed
conformation by hydrogen bonds are known, but a general
rule is not yet apparent.
Received 18 December 2011
Accepted 16 April 2012
PDB References:
CK21–335–resorufin, 3u9c;
CK21–325/CK20327–350–
AMPPN(P), 3u87.
1. Introduction
1.1. The hinge/aD region of eukaryotic protein kinases
The catalytic core of eukaryotic protein kinases (EPKs),
which were structurally characterized for the first time in the
case of cAMP-dependent protein kinase (CAPK; Knighton et
al., 1991), is composed of two domains that harbour the ATP-
binding site between them (Fig. 1). Catalytically competent
ATP binding is accomplished by determinants of the two
domains themselves and additionally by the hinge region
(Zheng et al., 1993), which links them in a way that permits
limited interdomain mobility (Cox et al., 1994).
The hinge forms hydrogen bonds to the adenine moiety of
ATP via its peptide backbone (Zheng et al., 1993; Fig. 2a).
Moreover, in CAPK and many other EPKs it possesses a
ribose anchor, i.e. a negatively charged side chain that co-
ordinates the 20- and 30-hydroxy groups of the ATP ribose and
is typically located in the transition section between the hinge
and the subsequent helix D (Fig. 1). Consequently, this
extended hinge region (termed the ‘hinge/D region’ in the
following) is also a pharmacologically important determinant
for the binding of ATP-competitive EPK inhibitors (Traxler &
Furet, 1999).
In recent years, Taylor and coworkers (Kornev et al., 2008;
Taylor & Kornev, 2011) have developed the spine concept,
which assigns additional significance to the hinge/D region:
in CAPK, Met128, which is the starting residue of helix D, is
an integral part of the so-called ‘catalytic spine’. The catalytic
spine and its pendant, the regulatory spine, are two conserved
stacks of hydrophobic residues that penetrate the catalytic
core and cross the interdomain space (Fig. 1). The regulatory
spine is a sine qua non of an active EPK, while the catalytic
spine requires the adenine group of ATP for full completion
(Fig. 1); it is thus periodically opened and re-established
during the catalytic cycle.
1.2. Hinge/aD-region plasticity in human CK2a
The study presented here deals with the hinge/D region
of CK2, the catalytic subunit of protein kinase CK2, which
can associate with the noncatalytic subunit CK2 to form a
heterotetrameric holoenzyme (Niefind et al., 2001). CK2 is an
acidophilic Ser/Thr kinase of the CMGC subgroup of EPKs.
Its association with a variety of diseases (Guerra & Issinger,
2008) renders it an attractive drug target (Trembley et al.,
2010). CK2 is therefore the subject of inhibitor-design studies
(Battistutta, 2009), and in this context the fluorescent dye
resorufin (Fig. 3a) has recently been identified as an ATP-
competitive CK2 inhibitor (Sandholt et al., 2009; Fritz et al.,
2009).
In the first structure of the CK2 subunit to be determined
(Niefind et al., 1998), an unconventional hinge/D region
conformation (compared with CAPK and the other EPK
structures known at the time) was discovered. This EPK-
atypical conformation was found in all subsequent CK2 and
CK2 holoenzyme structures determined until 2005, when the
first CK2 structure with a conformation of the hinge/D
region more similar to that in CAPK was published (Yde et al.,
2005).
This alternative hinge/D conformation, which was referred
to as the ‘closed’ conformation (grey region in Fig. 1) by Raaf,
Brunstein et al. (2008) in order to distinguish it from the ‘open’
conformation (blue region in Fig. 1) originally described
(Niefind et al., 1998), occurred in several further CK2
structures (Raaf, Klopffleisch et al., 2008; Zhou et al., 2009;
Raaf et al., 2009; Lo´pez-Ramos et al., 2010). An initial cluster
analysis (Raaf, Klopffleisch et al., 2008) suggested that maize
CK2 occurs exclusively with the open hinge/D conforma-
tion while human CK2 can adopt either conformation, a
distinction that was confirmed by a rigorous statistical analysis
including all CK2 structures available at the time (Niefind et
al., 2009). A survey of the Protein Data Bank (PDB) revealed
that nine of the 28 entries containing human CK2 (which
were without exception C-terminal deletion constructs or
degradation products) showed the hinge/D region in its
closed version (shown in bold in Table 1).
The functional and pharmacological importance of the
hinge/D region makes it desirable to understand the factors
that govern its conformational state in order to finally be
capable of predicting it. A necessary prerequisite to approach
this goal is to estimate and to eliminate the effects of crystal-
packing constraints and of special crystallization conditions.
Currently, the majority of the human CK2 structures in the
PDB originate from a monoclinic crystal form (No. 1 in
Table 1) in which the packing density is fairly high (39%
solvent content). Both hinge/D conformations can exist in
these crystals, but the open conformation is distinctly more
frequent (>80%) and occurs in particular in the apo structure
PDB entry 1na7, i.e. in the absence of a stabilizing ATP-site
ligand (Pechkova et al., 2003). These observations indicate a
preference for the open conformation in this crystal form,
possibly owing to the fact that in the open conformation
crystalline neighbours cover 254 A˚2 of the surface area of the
hinge/D region on average, which is significantly more than
in the closed conformation (157.2 A˚2; Table 1).
To avoid any crystal-packing bias, here we compare a set of
human CK2 structures, among them a novel CK2–resorufin
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Figure 1
Overview of protein kinase architecture using the example of CK2. The
catalytic protein kinase core, indicated in green (N-terminal domain) or
red (C-terminal domain), is penetrated by the regulatory spine (R-spine)
and the catalytic spine (C-spine). The hinge/D region is drawn in blue
(open conformation with Phe121 turned towards the outside) or grey
(closed conformation with Phe121 turned towards the inside, i.e. as part
of the C-spine). The N-terminal segment (magenta) folding back towards
the C-terminal domain is a typical feature of CK2. This figure was
prepared using PyMOL (Schro¨dinger LLC) from the CK21–325/
CK20327–350–AMPPN(P) complex structure (PDB entry 3u87). The
closed conformation of the hinge/helix D region (coloured grey) was
drawn from the CK21–335–resorufin complex (PDB entry 3u9c).
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Figure 2
The hinge/D-region conformations in the four structures with low-density tetragonal crystal packing. In all parts of the figure, which was prepared with
a combination of BobScript (Esnouf, 1997) and Raster3D (Merritt & Bacon, 1997), the structure of the complex of CK2 with the inhibitor CX-4945
(PDB entry 3nga; Ferguson et al., 2011) serves as a reference representing the open hinge/D conformation (black bonds, black water molecules, grey
CX-4945 molecule). The pieces of electron density stem from maps that were averaged over the two CK2 chains of the asymmetric unit using the
corresponding routines in Coot (Emsley et al., 2010). A cutoff level of 1 was applied for the illustration. Colour code for pieces of averaged density:
ATP-site ligand, blue; enzyme matrix, green. (a) CK21–325/CK20327–350 in complex with AMPPN(P) and magnesium ions. Two hydrogen bonds from
AMPPN to the hinge region as well as coordinative bonds to the Mg2+ ion are drawn as magenta dotted lines. (b) CK21–335 in complex with resorufin. (c)
Rat CK21–335 (identical to human CK21–335) crystallized without a defined ATP-site ligand. Glycerol from the cryosolution instead occupies the ATP
site.
structure, originating from tetragonal crystals grown under
similar conditions to the monoclinic crystals but comprising
a crystalline arrangement in which the hinge/D region is
largely free from crystal contacts.
2. Materials and methods
2.1. Selection of human CK2a structures
The CK2 structures primarily discussed here were deter-
mined from tetragonal crystals (space group P43212, packing
No. 5 in Table 1) containing two independent chains per
asymmetric subunit. The loose packing of these crystals (mean
solvent content of 61.6%) results in diffraction data sets with
poor resolution (Table 2) but also results in sufficient space to
allow plasticity of the hinge/D region.
To date, this low-density tetragonal crystal form has
appeared three times in the literature representing different
functional states, namely (i) with apo CK2 from rat
(fragment 1–335, which is identical to human CK21–335; PDB
entry 2r7i; Zhou et al., 2009); (ii) with human CK21–335 in
complex with the high-affinity ATP-competitive inhibitor
CX-4945 (Siddiqui-Jain et al., 2010; PDB entry 3nga; Ferguson
et al., 2011); and (iii) with the chimeric construct CK21–325/
CK20327–350 in complex with the ATP analogue AMPPNP
(PDB entry 3rp0; Bischoff, Raaf et al., 2011). Here, we opti-
mized two of these structures as far as possible (see below)
and supplemented them with the cocrystal structure of human
CK21–335 with resorufin (Table 2).
It is notable that the crystallization conditions were similar
in all four cases, with a medium-length polyethylene glycol as a
precipitant, a slightly acidic pH value (5.5–6.5) and a signifi-
cant concentration of sulfate ions (0.17–0.20M). The
CK21–335–CX-4945 complex structure (PDB entry 3nga) is a
special case insofar as it did not result from cocrystallization;
rather, the crystals were originally grown in the presence of
AMPPNP, which was subsequently substituted by extensive
soaking (Ferguson et al., 2011). However, a recent high-
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Table 1
Overview of human CK2 crystal packing in the PDB.
Fields that refer exclusively to the closed hinge/helix D conformation are shown in bold.
No.
Space group,
unit-cell
parameters
(A˚, )
Mean
solvent
content
(%)
Hinge/
helix D
confor-
mation
PDB codes with ligands
occupying the ATP site†
Mean surface of
hinge/D region
covered by
crystal contacts‡
(A˚2)
Crystallization essentials
Main precipitants§ Salt additives}
Method of
enzyme/ligand
combination
1 P21, a = 59,
b = 46,
c = 63,
 = 112
39.0 Closed 3bqc, 3c13 (emodin); 3mb6
(a difurandicarboxylic acid
derivative)
157.2 30–32% PEG 4000
(3bqc, 3c13);
36% PEG MME 5000
(3mb6)
(NH4)2SO4 (3mb6);
Li2SO4 (3bqc);
CH3COO(NH4)
(3c13)
Pre-incubation
(3bqc, 3c13);
soaking (3mb6)
Open 1na7 (apo); 1pjk, 2pvr [(adenylyl
imidodiphosphate (AMPPNP)];
3mb7 (a difurandicarboxylic acid
derivative); 3owj, 3owk, 3owl
(3-pyridocarbazole derivatives);
3pe1, 3pe2, 3r0t (CX-4945 and
relatives)
254.0 25% PEG 3500 (1na7);
30–32% PEG 4000
(3pe1, 3pe2, 3r0t);
36% PEG MME 5000
(1pjk, 2pvr, 3mb6,
3owj, 3owk, 3owl)
(NH4)2SO4 (3mb7,
3owj, 3owk, 3owl);
Li2SO4 (3pe1, 3pe2,
3r0t); CH3COONa
(1na7)
Pre-incubation
(3pe1, 3pe2, 3rot);
cocrystallization
(1pjk, 2pvr);
soaking (3mb7,
3owj, 3owk, 3owl)
2 P212121,
a = 48,
b = 76,
c = 78
31.0 Open 2zjw (ellagic acid); 3amy (apigenin);
3at2 (ethylene glycol);
3at3, 3at4 (pyridine derivatives)
154.7 25% ethylene glycol Pre-incubation
3 P212121,
a = 49,
b = 62,
c = 117
45.1 Open 3nsz [adenylyl phosphoramidate
(AMPPN)]
17.5 26% PEG 4000 (NH4)2SO4 Cocrystallization
4a P43,
a = b = 72,
c = 126
38.7 Closed 3fwq (apo); 3h30 (5,6-dichloro-
ribofuranosyl benzimidazole);
3juh [adenylyl imidodiphosphate
(AMPPNP)]
6.3 2 M (NH4)2SO4, 2 M NaCl (3fwq);
2.2 M sodium citrate (3h30);
1.5 M (NH4)2SO4, 0.2 M sodium citrate (3juh)
Pre-incubation
(3h30);
cocrystallization
(3juh)
4b P43,
a = b = 72,
c = 133
42.9 3rps (a tetrabromobenzotriazole
derivative)
3.2 4 M NaCl, 0.1 M sodium citrate Pre-incubation
5 P43212,
a = b = 127,
c = 125
61.6 Closed 2r7i (apo); 3u9c (resorufin) 22.1 25% PEG 3350 (2r7i);
30% PEG 8000 (3u9c)
Li2SO4 (2r7i);
(NH4)2SO4 (3u9c)
Pre-incubation
(3u9c)
Open 3nga (CX-4945); 3u87 (formerly
3rp0; chain A, AMPPNP; chain B,
AMPPN)
37.9 26% PEG 4000 (3nga);
15% PEG 8000,
15% glycerol (3u87)
(NH4)2SO4 Soaking (3nga);
cocrystallization
(3u87)
6 P63,
a = b = 175,
c = 93
61.7 Open 1jwh (CK2 holoenzyme; chain A,
AMPPNP, chain B, apo)
Chain A, 74.4;
chain B, 256.7
20% PEG 3350 K2HPO4 Cocrystallization
† For literature references and chemical details, see the corresponding entries in the PDB (http://www.rcsb.org). ‡ Calculated using AREAIMOL from the CCP4 suite (Winn et al.,
2011). All nonprotein atoms were neglected in these calculations. § Abbreviations: PEG, polyethylene glycol; PEG MME, polyethylene glycol monomethylether. } Further ions
were introduced by buffer substances and by sodium chloride in the protein stock solution.
resolution structure of the same complex (PDB entry 3pe1;
Battistutta et al., 2011) originating from pre-incubation of the
enzyme and the inhibitor prior to crystallization revealed no
significant difference in the hinge/D region from the original
structure (Ferguson et al., 2011).
After submission of this manuscript, three new human
CK2 structures with the low-density tetragonal crystal
packing were released (Papinutto et al., 2012). They are not
included in Table 1, but as discussed below they support the
insights from this work.
2.2. Protein preparation and crystallization
Human CK21–335 was recombinantly expressed in
Escherichia coli BL21 (DE3) cells and purified as described by
Raaf, Klopffleisch et al. (2008). Finally, the CK21–335 solution
was concentrated by ultrafiltration and rebuffered in 500 mM
NaCl, 25 mM Tris–HCl pH 8.5. The final protein concentration
was 10.0 mg ml1.
Resorufin was purchased from Sigma–Aldrich. A 10 mM
resorufin solution was prepared in the same buffer but with
the addition of 5% DMSO. Equal volumes of the CK21–335
solution and the resorufin stock solution were mixed, pre-
incubated for 45 min at room temperature and used in vapour-
diffusion crystallization experiments. CK21–335–resorufin
crystals (Fig. 3b) grew from drops consisting of equal volumes
of CK21–335–resorufin mixture and a reservoir solution
composed of 30% PEG 8000, 0.2M ammonium sulfate, 0.1M
sodium cacodylate pH 6.4. Details of the production and
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Table 2
Data-collection and refinement statistics.
Values in parentheses are for the highest shell.
Structure
CK21–335–resorufin
(PDB entry 3u9c)
CK21–325/CK20327–350–AMPPN(P)
(PDB entry 3u87; formerly 3rp0)
Apo CK21–335
(PDB entry 2r7i)
X-ray diffraction data collection
Space group P43212 P43212 P43212
Unit-cell parameters (A˚) a = b = 127.78, c = 125.77 a = b = 127.82, c = 125.33 a = b = 127.52, c = 126.41
Resolution (A˚) 19.9–3.2 (3.37–3.20) 36.7–2.9 (3.06–2.90) 50.0–3.0 (3.13–3.00)†
Rmerge (%) 17.8 (68.9) 10.3 (69.5) 15.4 (64.8)†
hI/(I)i 14.6 (3.9) 17.5 (3.6) 14.2 (2.8)†
Completeness (%) 99.6 (100.0) 99.5 (99.8) 99.6 (100.0)†
Multiplicity 10.2 (10.4) 9.7 (10.0) 7.2 (6.8)†
Wilson B factor (A˚2) 70.6 78.3 42.0†
Structure refinement and validation
Resolution (A˚) 19.9–3.2 36.7–2.9 20.0–3.0
No. of reflections 17632 23394 20291
No. of reflections in test set 881 1202 1050
Rwork/Rfree (%) 20.1/23.1 18.6/21.8 20.8/24.8
Composition of asymmetric unit
Protomers 2 2 2
Missing (disordered) residues Met1, Arg333–Gly335 Met1, Gln331–Arg349 Met1, Arg333–Gly335
ATP-site ligands 2 resorufin 1 AMPPNP, 1 AMPPN —
Further ligands 7 SO4
2, 1 Cl, 5 glycerol 4 Mg2+, 2 Cl, 2 SO4
2, 2 glycerol 9 SO4
2, 7 glycerol
Water molecules 55 51 61
Ramachandran plot quality‡
Most favoured 547 [90.7%] 535 [89.8%] 535 [89.0%]
Additionally allowed 53 [8.8%] 59 [9.9%] 61 [10.1%]
Generously allowed 2 [0.3%] 0 [0.0%] 4 [0.7%]
Disallowed 0 [0.0%] 2 [0.3%] 2 [0.3%]
R.m.s. deviations
Bond lengths (A˚) 0.002 0.006 0.002
Bond angles () 0.574 0.641 0.568
Dihedral angles () 10.9 11.8 13.7
† Data taken from Zhou et al. (2009) or from the corresponding PDB entry 2r7i and referring to space group P43. ‡ According to PROCHECK from the CCP4 suite (Winn et al.,
2011).
Figure 3
Cocrystallization of CK21–335 with resorufin. (a) Structure of resorufin.
(b) CK21–335 crystals grown in the presence of resorufin.
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crystallization of the CK21–325/CK20327–350 construct in the
presence of AMPPNP and magnesium ions have recently been
described (Bischoff, Raaf et al., 2011).
2.3. Diffraction data collection, structure determination and
optimization
X-ray diffraction data were collected from cryocooled
CK21–335–resorufin crystals (cryosolution: 30% PEG 8000,
20% glycerol, 0.2M ammonium sulfate, 0.1M sodium
cacodylate pH 6.4) at a temperature of 100 K on beamline 14.1
of the BESSY synchrotron, Berlin, Germany. The wavelength
was 0.91841 A˚. We used XDS (Kabsch, 2010) to integrate the
diffraction data and SCALA (Evans, 2006) from the CCP4
suite (Winn et al., 2011) to scale the data. We applied the same
procedure to process a CK21–325/CK20327–350 diffraction data
set that had been collected in the context of the published
structure 3rp0 (Bischoff, Raaf et al., 2011). These diffraction
data were different from the raw data underlying structure
3rp0 (Bischoff, Raaf et al., 2011), but the two corresponding
crystals had been grown under equivalent conditions.
The XDS integration runs were performed without
symmetry specification (i.e. in space group P1) and ran stably
without lattice constraints. After integration the space group
was automatically determined to be P41212 (or its enantio-
morph P43212) by the XDS routine CORRECT (Kabsch,
2010) in both cases and this assignment was confirmed by
POINTLESS (Evans, 2006) from the CCP4 suite (Winn et al.,
2011).
The high-resolution limits of the CK21–335–resorufin and
CK21–325/CK20327–350 diffraction data sets were determined
by visual inspection of single images and on the basis of the
hI/(I)i ratios in the last shells (Table 2). A possible reason for
the relatively high Rmerge values of the data sets (in particular
in the case of the CK21–335–resorufin complex) is an
increased portion of weak reflections caused by pseudo-
centring, as documented in Fig. 4. However, the Rmerge value
in the top intensity bin was lower than 4%, indicating the
absence of systematic errors.
Figure 4
Pseudo-centring of the low-density tetragonal crystal form and its consequences for X-ray diffraction. (a) Crystallographic unit cell with two pairs of
CK2 molecules. The two members of each pair are related by the translation vector (0, 0, 0.48). (b) u = 0 section of a native Patterson function. The
Patterson density was drawn with a cutoff of 20 (statistics over the whole unit cell). (c) Consequences of the pseudo-centring in the crystal packing for
X-ray diffraction illustrated by the (0kl) section of the CK21–335–resorufin diffraction data set with a high-resolution cutoff at 6 A˚. Odd l indices lead to
a systematic weakening of X-ray reflections in the region of small l indices. The figure was prepared with the reflection-data viewer in PHENIX (Adams
et al., 2010). All parts of the figure were prepared using data for the CK21–335–resorufin structure.
Finally, as a third data set, the apo CK21–335 structure
factors (PDB entry 2r7i; Zhou et al., 2009) were downloaded
from the PDB. In this case POINTLESS (Evans, 2006) also
assigned P41212 or its enantiomorph P43212 as the correct
space group, but owing to the lack of raw diffraction data no
full re-processing was performed.
The subsequent procedure was equivalent in all three cases.
The CK21–335–CX-4945 structure (PDB entry 3nga; Ferguson
et al., 2011), with all atomic coordinates corresponding to
water, ligands and hinge/D residues removed, served as a
starting point for refinement performed by PHENIX (Adams
et al., 2010) supported by manual optimization with Coot
(Emsley et al., 2010). Automatically assigned torsion-angle
NCS restraints were applied in phenix.refine runs. Optimal
weighting factors between X-ray and stereochemistry terms
were determined automatically by PHENIX.
2.4. Molecular-replacement and refinement test calculations
To rationalize previous molecular-replacement and refine-
ment problems with PDB entries 2r7i (Zhou et al., 2009) and
3rp0 (Bischoff, Raaf et al., 2011), we performed retrospective
molecular-replacement and refinement test calculations using
MOLREP (Vagin & Teplyakov, 2010), Phaser (McCoy et al.,
2007) and REFMAC (Murshudov et al., 2011) in the versions
embedded in release 6.2.0 of the CCP4 suite (Winn et al.,
2011).
2.5. Calculation of differential solvent accessibilities
The solvent-accessible surface areas of CK2 chains
covered by symmetry equivalents (Table 1, column 6) were
calculated using AREAIMOL from the CCP4 suite (Winn et
al., 2011). All nonprotein atoms were neglected in these
calculations.
3. Results and discussion
3.1. Structural optimization
PDB entries 2r7i and 3rp0, which are two of the structures
with the low-density tetragonal packing No. 5 in Table 1, were
published with the lower symmetrical space group P43 rather
than P43212 (Zhou et al., 2009; Bischoff, Raaf et al., 2011).
In the case of 3rp0 from our group, data processing and
molecular-replacement searches with Phaser (McCoy et al.,
2007) from the CCP4 package (Winn et al., 2011) initially
indicated P43212 as the correct space group, but subsequent
refinement runs with REFMAC stuck at Rfree values of around
40%. Convergence could only be achieved by reducing the
symmetry to space group P43, but at the expense of more
model bias. The authors of structure 2r7i (Zhou et al., 2009)
encountered similar problems and likewise reduced the
symmetry in order to overcome them (Y. Shen, personal
communication).
Subsequently, the publication of the isomorphous structure
3nga (Ferguson et al., 2011) indicated that refinement in space
group P43212, and thus with a reduced asymmetric unit
containing two rather than four independent subunits, should
be possible. This was confirmed here by taking the ligand-free
3nga coordinates as a starting point for refinement, which was
successful (Table 2).
P43212-based refinement resulted in structures of signifi-
cantly better quality. For instance, in all four CK21–335 chains
of the original PDB entry 2r7i (Zhou et al., 2009) several
residues of the ATP-binding loop and the 45 loop (Fig. 1)
were omitted owing to disorder; after the novel refinement the
45 loops of both chains and one of the ATP-binding loops
were well defined. A glycerol molecule from the cryosolution
was visible at the ATP site (Fig. 2c).
In the case of the CK21–325/CK20327–350 structure
(Bischoff, Raaf et al., 2011) the optimization depended on the
processing of better raw data (see above) combined with
assignment of the higher symmetrical space group. Here, clear
electron density indicated the presence of the nucleotide
analogue in the ATP-binding site (Fig. 2a), yet in the region of
the imido-triphospho moiety the picture was not unambig-
uous. In a similar case (PDB entry 3nsz), Ferguson et al. (2011)
assumed hydrolysis under the acidic pH conditions of the
crystallization drop, deleted the terminal phosphono moiety of
AMPPNP and referred to the remaining hydrolysis product
adenylyl phosphoamidate as ‘AMPPN’. We followed this
practice partly and placed AMPPN into one chain and
AMPPNP into the other accompanied by two Mg2+ ions.
3.2. Retrospective test calculations
In order to understand the previous convergence problems
for PDB entries 2r7i and 3rp0, we compared the methods
sections of the corresponding publications and found that,
in contrast to Zhou et al. (2009) and Bischoff, Raaf et al.
(2011), Ferguson et al. (2011) had used MOLREP (Vagin &
Teplyakov, 2010) rather than Phaser (McCoy et al., 2007) for
molecular-replacement calculations. Therefore, we performed
test calculations with the three P43212-scaled data sets in
Table 2 plus the structure factors belonging to PDB entry 3nga
using the CCP4-integrated versions of Phaser and MOLREP
followed by refinement with REFMAC (Murshudov et al.,
2011). In all cases MOLREP led to refinable solutions, while
the Phaser solutions were not completely wrong (consistent
with Rfree values of around 40%) but were too inaccurate for
subsequent convergence in refinement.
A possible explanation for this difference is that the crys-
tallographic unit cell contains eight pairs of CK2 chains of
approximately the same orientation related by the translation
vector (0, 0, 0.48) (Fig. 4a). This special arrangement leads to
a pseudo-origin peak in a native Patterson function (Fig. 4b)
and to systematic weakening of X-ray reflections with an odd
l index (Fig. 4c). Unlike Phaser, MOLREP automatically
detects and exploits such translation vectors.
3.3. Complex structure of human CK2a1–335 with resorufin
The cocrystallization of resorufin and CK21–335 led to
crystals with a significantly violet colour (Fig. 3b). The electron
density at the ATP-binding site documents the binding of
resorufin (Fig. 2b). However, it does not cover the ligand
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completely, which led to high temperature factors and occu-
pancies significantly below 1. This reflects a relatively low
affinity, which is consistent with the micromolar Ki value
(1.3 mM) reported by Sandholt et al. (2009).
The low resolution of 3.2 A˚ and the limited quality of the
electron-density map around the ligand only allow a preli-
minary view of the details of resorufin binding. At such a
resolution water molecules often cannot be identified unam-
biguously. Nevertheless, it appears that resorufin penetrates
relatively deeply into a region of the ATP-binding site that is
typically blocked by a conserved water molecule (Battistutta
et al., 2007; Fig. 2b). Harboured in a well characterized
hydrophobic pocket (Yde et al., 2005; Battistutta, 2009) and
flanked by nonpolar residues on both sides (Ile174 and
Met163 on the C-terminal domain side and Val66 and Phe113
on the opposite side), resorufin binding requires no clearly
defined hydrogen bonds to the enzyme matrix, in particular
not to the hinge/D region.
A curious feature of the crystal packing of the CK2–
resorufin complex that was not found in any other human or
maize CK2 crystal form is an ‘arginine zipper’, i.e. a set of six
alternating arginine side chains from two symmetry-
equivalent enzyme subunits (Fig. 5a). A similar yet less well
formed arginine-zipper motif is present in the second low-
density crystal form of Table 1 corresponding to the CK2
holoenzyme (Fig. 5b; Niefind et al., 2001). A recent analysis
has shown that this ‘electrostatics-defying interaction between
arginine termini’ (Pednekar et al., 2009) occurs surprisingly
frequently and is even a driving force of protein–protein
interactions. To our knowledge, however, such an extended
motif as the arginine zipper in Fig. 5 has not been described
before.
3.4. Hinge/aD-region preferences
The hinge/D region of each chain of the CK21–335–
resorufin structure is found in the closed conformation
(Fig. 2b). Assignment to either the open or the closed
conformation can be easily performed for any CK2 structure,
since an unambiguous flag exists in Phe121 (Bischoff, Raaf
et al., 2011; Battistutta & Lolli, 2011). Phe121 is topologically
equivalent to the catalytic spine member Met128 of CAPK,
and like the latter it can bury its side chain in a hydrophobic
cavity and thus complete the catalytic spine. This ‘Phe121-in’
state (Fig. 1), as observed in the CK21–335–resorufin complex
(Fig. 2b), is equivalent to the closed hinge/D region confor-
mation, which is thus ‘canonical’ with respect to CAPK and
other EPKs (Bischoff, Raaf et al., 2011; Battistutta & Lolli,
2011). It is atypical, however, with respect to maize CK2, to
the CK2 holoenzyme and to the paralogous isoform human
CK20 (Bischoff, Olsen et al., 2011), all of which display an
open hinge/D region with Phe121 turned to an ‘out’ state
(Fig. 1). In this state the aromatic side chain fills a space that is
otherwise occupied by Lys122 (Battistutta & Lolli, 2011).
Similar to the CK21–335–resorufin complex, the hinge/D
region adopts a closed conformation in apo CK21–335
(Fig. 2c), while it is fixed in the open conformation in both
subunits of the complex with the inhibitor CX-4945 (Ferguson
et al., 2011; the black reference in Fig. 2 representing the open
conformation) and of the CK21–325/CK20327–350–AMPPN(P)
complex (Fig. 2a). The statistical basis of this equipartition,
with four chains open and four chains closed, is thin, but
nevertheless it permits the preliminary conclusion that this
low-density crystal packing does not per se prefer either of the
two conformational states over the other.
This notion is supported by the fact that the crystal contacts
of the hinge/D regions are small in this packing (No. 5 in
Table 1) and, in contrast to the monoclinic crystal form, do not
differ significantly between the open and the closed hinge/D
conformations. It was further confirmed by three CK2
structures recently published by Papinutto et al. (2012) that
likewise belong to packing No. 5 in Table 1: in these structures
one of the two CK2 chains of the asymmetric unit adopts an
open hinge/D region conformation and the other adopts a
closed conformation.
Notably, the electron densities and temperature factors of
the hinge/D regions reveal the following tendencies: (i) in
each of the eight chains the hinge/D region is among the
zones with the largest internal disorder and (ii) the degree of
disorder in the hinge/D region is significantly higher in the
chains with closed conformation. These findings suggest that
there is not only conformational ambiguity in the hinge/D
region of human CK2 but rather a dynamic conformational
equilibrium in solution that can be resolved by suitable ligands
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Figure 5
An ‘arginine zipper’ mediating a protein–protein interaction at a crystal
contact. The guanidinium moieties of six arginine side chains are
arranged in a helical manner and are provided alternately by each of the
two protein subunits. The positive charges are balanced by neighbouring
negatively charged side chains and ions (not drawn). The pieces of
electron density were drawn with a 1 cutoff level. The figure was
prepared with BobScript (Esnouf, 1997) and Raster3D (Merritt & Bacon,
1997). (a) Arginine zipper in the low-density tetragonal crystal form
represented by the CK21–335–resorufin structure. (b) Distorted arginine
zipper in the low-density hexagonal crystal form of the CK2 holoenzyme
(PDB entry 1jwh; Niefind et al., 2001).
favouring one of the two conformations either by stabilizing it
or by destabilizing the other conformation.
The CK21–325/CK20327–350–AMPPN(P) complex (Fig. 2a)
suggests that the physiological cosubstrate ATP that normally
causes the final closure of the catalytic spine (Kornev et al.,
2008; Taylor & Kornev, 2011; Fig. 1) in this case supports the
open hinge/D conformation with an incomplete catalytic
spine. However, it is unclear how this is achieved since the
only interactions of AMPPN(P) with the hinge/D region are
hydrogen bonds to Glu114 and Val116 (Fig. 2a), i.e. to the
N-terminal part of the hinge/D region, in which the two
conformations are not yet different.
3.5. Which factors are responsible for the hinge/aD-region
conformation of CK2a?
In all of its crystal structures (more than 30) maize CK2
exists with an open hinge/D conformation, irrespective of the
ligand, the crystallization conditions or the crystal packing.
Thus, in maize CK2 strong intramolecular constraints must
exist that enforce an unambiguous local conformation (in
addition to that atypical for EPKs; Bischoff, Raaf et al., 2011;
Battistutta & Lolli, 2011). Initial plausible ideas about the
critical amino acids that cause this conformational discrimi-
nation have recently been suggested (Battistutta & Lolli,
2011).
In human CK2, however, the intrinsic constraints are
significantly weaker, so that external factors such as ligand
binding, temperature, ionic strength, pH value and crystal
packing come into play. We previously assumed (Niefind &
Issinger, 2010) that CK2, although not binding directly to the
hinge/D region, might shift the conformational equilibrium
towards the open state, but owing to the lack of more than one
structure (PDB entry 1jwh; Niefind et al., 2001) this remains an
unproven hypothesis.
One clear tendency, however, is visible from an inspection
of Table 1, namely that high concentrations of lyotropic salts
enforce the closed conformation: in all structures of packing
4a in Table 1 and the very similar packing 4b the hinge/D
region is closed and typically relatively well ordered. These
structures originate from high-density tetragonal crystal
packings in which the hinge/D region is not involved in (and
thus is not affected by) crystal contacts. Modelling of the open
hinge/D state into these structures with Coot (Emsley et al.,
2010) revealed that it would likewise be compatible with these
crystal packings.
A common and distinctive feature of these structures is that
the corresponding crystallization media are free of poly-
ethylene glycol and are dominated by high concentrations of
salts with lyotropic anions (citrate, sulfate and chloride). As
known from the ‘salting-out’ effect of proteins and from
hydrophobic interaction chromatography, such anions support
hydrophobic interactions (Queiroz et al., 2001) by interacting
with water, lowering its surface tension and disturbing the
water shell around hydrophobic surfaces.
With regard to human CK2, this means that the closed
hinge/D conformation is strongly supported by lyotropic
salts because (i) only in this conformation can Phe121 harbour
its aromatic side chain in the hydrophobic C-spine environ-
ment and (ii) water molecules that stabilize the open hinge/D
conformation by occupation of a cavity near Asn118 between
the hinge and the rest of the enzyme (Fig. 2a) are removed,
as noted previously by Battistutta & Lolli (2011). It will be
interesting to investigate in the future whether chaotropic
anions such as nitrate or thiocyanate have the opposite effect
and favour the open hinge/D conformation.
The dominance of this ‘high lyotropic salt effect’ is relevant
to the open question of which of the two hinge/D confor-
mations of human CK2 is the active one. In previous studies
(Bischoff, Raaf et al., 2011; Niefind & Issinger, 2010) we
favoured the open state because of the equivalence to maize
CK2 and owing to the observation that binding of an ATP
analogue is correlated in most cases with an open hinge/C
region (PDB entries 1pjk, 2pvr, 3nsz, 3u87 and 1jwh; Table 1).
Recently, however, the only exception (PDB entry 3juh; Yde
et al., 2005) was taken as an argument that human CK2might
also be active with a closed hinge/C region (Battistutta &
Lolli, 2011), but the study presented here suggests that the
exceptional combination of AMPPNP binding and closed
hinge/D conformation is a consequence of the dominating
high citrate concentration and does not represent a functional
state. This conclusion is also consistent with the early obser-
vation that increasing chloride concentrations strongly reduce
the catalytic activity of human CK2 (Grankowski et al.,
1991).
In any case, the example of 3juh demonstrates that genuine
effects of ATP-site ligands on the hinge/D conformation can
best be observed under moderate salt concentrations with
variants of (poly)ethylene glycol as precipitant. Fortunately,
under such conditions apo CK2 itself does not show a clear
conformational preference: as the apo structures 1na7 and 2r7i
demonstrate, subtle effects [such as possibly the pH value or
the nature of the salt additive (the strongly lyotropic sulfate in
2r7i versus the weakly lyotropic acetate in 1na7)] can deter-
mine whether the hinge/D region is open (1na7) or closed
(2r7i), again illustrating the small size of the energetic differ-
ence between the two states.
As indicated in x1, crystal-packing constraints may cause a
certain bias in the monoclinic crystal form (No. 1 in Table 1)
but they do not dominate. This was impressively shown by
Lo´pez-Ramos et al. (2010) by the comparison of structures
3mb6 and 3mb7. In both cases the corresponding monoclinic
CK21–335 crystals originally grew under conditions that
were known to support the open hinge/D conformation
(Ermakova et al., 2003), but extensive soaking (one week) with
the respective ATP-competitive inhibitors enforced the
closed hinge/D conformation in one case, while in the other
the open conformation was retained. Neither of these two
inhibitors forms hydrogen bonds similar to the adenine moiety
of ATP, i.e. to Glu114 and Val116 in the N-terminal part
of the hinge/D region (Fig. 2a). Rather, Lo´pez-Ramos et al.
(2010) identified Asn118 as a critical residue: in structure
3mb7 (but not in 3mb6) the Asn118 side chain forms a
hydrogen bond to the corresponding inhibitor and requires
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the hinge/D region in its open conformation for this
interaction.
An equivalent hydrogen bond is not present if the open
hinge/D conformation is combined with AMPPNP or with
the inhibitor CX-4945 (Fig. 2a). Thus, while no general rule
is apparent so far, in the case of particular ligands single
enzyme–ligand hydrogen bonds may be critical for the deci-
sion between the open and the closed hinge/D conformation,
suggesting that virtual screening efforts should always include
both hinge/D conformations.
For further experimental investigations of the conforma-
tional plasticity of human CK2, it is noteworthy that the
closed hinge/D conformation in structure 3mb6 (as opposed
to 3mb7) suffers from a high degree of disorder, which may
indicate a considerable bias that enters into play when the
soaking technique is applied in a case in which crystal-packing
constraints are not eliminated. Therefore, the low-density
tetragonal crystals of the CK2–resorufin complex investi-
gated in this work provide a more suitable crystalline basis for
the study of such ligand-imposed conformational switches of
the hinge/D region in human CK2.
4. Accession codes
The final atomic coordinates and structure-factor amplitudes
of the CK21–335–resorufin complex are available from the
PDB (accession code 3u9c). The improved structure of the
CK21–325/CK20327–350–AMPPN(P) complex was deposited in
the PDB under accession code 3u87, which replaces entry
3rp0.
We are grateful to the staff of the BESSY synchrotron,
Berlin, Germany for assistance with data collection and to
Elena Brunstein for excellent technical assistance in protein
purification and crystallization. The valuable comments of
Professor Yuequan Shen, Nankai University, Tianjin, People’s
Republic of China on the refinement problems with structure
2r7i are gratefully acknowledged. This work was funded by the
Danish Research Council (grant No. 21-01-0511) and by the
Deutsche Forschungsgemeinschaft (DFG; grant NI 643/4-1).
References
Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221.
Battistutta, R. (2009). Cell. Mol. Life Sci. 66, 1868–1889.
Battistutta, R., Cozza, G., Pierre, F., Papinutto, E., Lolli, G., Sarno, S.,
O’Brien, S. E., Siddiqui-Jain, A., Haddach, M., Anderes, K.,
Ryckman, D. M., Meggio, F. & Pinna, L. A. (2011). Biochemistry,
50, 8478–8488.
Battistutta, R. & Lolli, G. (2011). Mol. Cell. Biochem. 356, 67–73.
Battistutta, R., Mazzorana, M., Cendron, L., Bortolato, A., Sarno, S.,
Kazimierczuk, Z., Zanotti, G., Moro, S. & Pinna, L. A. (2007).
Chembiochem, 8, 1804–1809.
Bischoff, N., Olsen, B., Raaf, J., Bretner, M., Issinger, O.-G. & Niefind,
K. (2011). J. Mol. Biol. 407, 1–12.
Bischoff, N., Raaf, J., Olsen, B., Bretner, M., Issinger, O.-G. & Niefind,
K. (2011). Mol. Cell. Biochem. 356, 57–65.
Cox, S., Radzio-Andzelm, E. & Taylor, S. S. (1994). Curr. Opin. Struct.
Biol. 4, 893–901.
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta
Cryst. D66, 486–501.
Ermakova, I., Boldyreff, B., Issinger, O.-G. & Niefind, K. (2003). J.
Mol. Biol. 330, 925–934.
Esnouf, R. M. (1997). J. Mol. Graph. 15, 132–134.
Evans, P. (2006). Acta Cryst. D62, 72–82.
Ferguson, A. D., Sheth, P. R., Basso, A. D., Paliwal, S., Gray, K.,
Fischmann, T. O. & Le, H. V. (2011). FEBS Lett. 585, 104–110.
Fritz, G., Issinger, O.-G. & Olsen, B. B. (2009). Int. J. Oncol. 35, 1151–
1157.
Grankowski, N., Boldyreff, B. & Issinger, O.-G. (1991). Eur. J.
Biochem. 198, 25–30.
Guerra, B. & Issinger, O.-G. (2008). Curr. Med. Chem. 15, 1870–1886.
Kabsch, W. (2010). Acta Cryst. D66, 125–132.
Knighton, D. R., Zheng, J.-H., Ten Eyck, L. F., Ashford, V. A., Xuong,
N.-H., Taylor, S. S. & Sowadski, J. M. (1991). Science, 253, 407–414.
Kornev, A. P., Taylor, S. S. & Ten Eyck, L. F. (2008). Proc. Natl Acad.
Sci. USA, 105, 14377–14382.
Lo´pez-Ramos, M., Prudent, R., Moucadel, V., Sautel, C. F., Barette,
C., Lafaneche`re, L., Mouawad, L., Grierson, D., Schmidt, F.,
Florent, J. C., Filippakopoulos, P., Bullock, A. N., Knapp, S., Reiser,
J. B. & Cochet, C. (2010). FASEB J. 24, 3171–3185.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D.,
Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.
Merritt, E. A. & Bacon, D. J. (1997).Methods Enzymol. 277, 505–524.
Murshudov, G. N., Skuba´k, P., Lebedev, A. A., Pannu, N. S., Steiner,
R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011).
Acta Cryst. D67, 355–367.
Niefind, K., Guerra, B., Ermakowa, I. & Issinger, O.-G. (2001).
EMBO J. 20, 5320–5331.
Niefind, K., Guerra, B., Pinna, L. A., Issinger, O.-G. & Schomburg, D.
(1998). EMBO J. 17, 2451–2462.
Niefind, K. & Issinger, O.-G. (2010). Biochim. Biophys. Acta, 1804,
484–492.
Niefind, K., Raaf, J. & Issinger, O.-G. (2009). Cell. Mol. Life Sci. 66,
1800–1816.
Papinutto, E., Ranchio, A., Lolli, G., Pinna, L. A. & Battistutta, R.
(2012). J. Struct. Biol. 177, 382–391.
Pechkova, E., Zanotti, G. & Nicolini, C. (2003). Acta Cryst. D59,
2133–2139.
Pednekar, D., Tendulkar, A. & Durani, S. (2009). Proteins, 74,
155–163.
Queiroz, J. A., Tomaz, C. T. & Cabral, J. M. S. (2001). J. Biotechnol.
87, 143–159.
Raaf, J., Brunstein, E., Issinger, O.-G. & Niefind, K. (2008). Chem.
Biol. 15, 111–117.
Raaf, J., Issinger, O.-G. & Niefind, K. (2009). J. Mol. Biol. 386, 1212–
1221.
Raaf, J., Klopffleisch, K., Issinger, O.-G. & Niefind, K. (2008). J. Mol.
Biol. 377, 1–8.
Sandholt, I. S., Olsen, B. B., Guerra, B. & Issinger, O.-G. (2009).
Anticancer Drugs, 20, 238–248.
Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F.,
O’Brien, S. E., Bliesath, J., Omori, M., Huser, N., Ho, C., Proffitt, C.,
Schwaebe, M. K., Ryckman, D. M., Rice, W. G. & Anderes, K.
(2010). Cancer Res. 70, 10288–10298.
Taylor, S. S. & Kornev, A. P. (2011). Trends Biochem. Sci. 36, 65–77.
Traxler, P. & Furet, P. (1999). Pharmacol. Ther. 82, 195–206.
Trembley, J. H., Chen, Z., Unger, G., Slaton, J., Kren, B. T., Van Waes,
C. & Ahmed, K. (2010). Biofactors, 36, 187–195.
Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25.
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
Yde, C. W., Ermakova, I., Issinger, O.-G. & Niefind, K. (2005). J. Mol.
Biol. 347, 399–414.
Zheng, J., Knighton, D. R., Ten Eyck, L. F., Karlsson, R., Xuong, N.,
Taylor, S. S. & Sowadski, J. M. (1993). Biochemistry, 32, 2154–2161.
Zhou, W. H., Qin, X. H., Yan, X. J., Xie, X. Q., Li, L., Fang, S. S., Long,
J. F., Adelman, J., Tang, W.-J. & Shen, Y. Q. (2009). Chin. Sci. Bull.
54, 220–226.
research papers
892 Klopffleisch et al.  Protein kinase CK2 catalytic subunit Acta Cryst. (2012). D68, 883–892
